首页 | 本学科首页   官方微博 | 高级检索  
     

降压药物在妊娠期高血压疾病中应用的争议与发展
引用本文:林其德,李青. 降压药物在妊娠期高血压疾病中应用的争议与发展[J]. 中国计划生育和妇产科, 2013, 0(3): 19-21
作者姓名:林其德  李青
作者单位:上海交通大学医学院附属仁济医院妇产科,上海200127
摘    要:妊娠期高血压疾病(hypertensive disorders of pregnancy,HDP)是产科最重要合并症之一,严重影响母婴健康。然而,何时采用降压治疗、如何正确应用降压药物在HDP的治疗中始终存在争议,并在争议中不断发展。循证医学显示,肼苯哒嗪和硝苯地平已不再是HDP降压治疗的一线药物,而拉贝洛尔、尼卡地平也许是更好的选择。

关 键 词:妊娠期高血压疾病  降压药物  发展  争议

The controversy and development of antihypertensive agents using for the hypertensive disorders of pregnancy
LIN Qi - de,LI Qing. The controversy and development of antihypertensive agents using for the hypertensive disorders of pregnancy[J]. Chinese Journal of Family Planning & Gynecotokology, 2013, 0(3): 19-21
Authors:LIN Qi - de  LI Qing
Affiliation:Department of Gynaecology and Obstetrics, Renfi Hospital Affiliated to Shanghai Jiaotong University School of Medicine, 200127 Shanghai, P. R. China
Abstract:Hypertensive disorders of pregnancies remain a most important part of pregnancy complications, which seriously affect both mothers and fetus. However when to use and how antihypertensive agents to use have remained controversial and developable. Evidence based analysis showed that Hydralazine and Nifedipine were no longer the first choice, but Labetalol and Nicardipine may be a good choice.
Keywords:hypertensive disorders of pregnancy  antihypertensive agents  develop  controversy
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号